Propanc Biopharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, specializing in the development of novel cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s core product is PRP, a proprietary pancreatic proenzyme formulation designed as a long-term therapy to prevent tumor recurrence and metastasis by targeting and eradicating cancer stem cells. PRP acts as an epithelial-mesenchymal transition (EMT) modulator, suppressing tumor growth, inhibiting angiogenesis, and inducing cancer cell death. Propanc is also developing a synthetic backup compound called Rec-PRP as part of its drug pipeline. The company’s product development is supported by collaborations with academic institutions including the Universities of Jaén and Granada in Spain, where joint drug discovery and research programs are underway. In recent developments, Propanc is advancing PRP toward a Phase 1B First-In-Human clinical trial scheduled for 2026 involving 30 to 40 advanced cancer patients, with GMP manufacturing scale-up achieving high purity standards. The company has initiated a strategic pharma partnering initiative with prominent cancer research institutes and global biomedical companies to support clinical development and commercialization. Additionally, Propanc has embarked on a strategic acquisition plan targeting Digital Asset Treasury (DAT) companies trading below market cap to net asset value, aiming to diversify its asset base and strengthen its financial position. This initiative is backed by a securities purchase agreement for up to $100 million with Hexstone Capital LLC, a family office with investments in digital assets, enabling Propanc to accelerate its R&D and expand its development programs beyond oncology. Propanc Biopharma was founded with a focus on enzyme therapy for solid tumors and holds a robust intellectual property portfolio with numerous granted patents and pending applications covering key markets. The company operates primarily in Australia with ongoing research partnerships in Spain and targets major pharmaceutical markets worldwide with its innovative proenzyme-based therapeutic approach designed to revolutionize cancer treatment by reducing metastasis and improving patient survival outcomes. Propanc’s efforts are geared toward addressing the high unmet medical need in solid tumor cancers, initially focusing on pancreatic, ovarian, and colorectal cancer indications, with plans to broaden its clinical pipeline and commercial reach. The strategic shift toward integrating digital asset acquisitions alongside its core biopharma business marks a unique financing and growth model in the biotechnology sector, aiming to enhance shareholder value while maintaining a strong focus on its proprietary proenzyme cancer therapies. Propanc’s management team has strengthened its leadership recently with new appointments to support this transformative phase of clinical and corporate growth. Overall, Propanc Biopharma combines innovative scientific research with strategic financial initiatives to advance cancer treatment and shareholder value in a competitive biopharmaceutical environment.
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations